MoonLake Immunotherapeutics (MLTX)
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$227.3M
- Total assets
- $424.4M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $244.8M
- Operating income
- -$244.8M
- Income tax
- $611.0K
- Net income
- -$230.3M
- EPS (basic)
- $-3.53
- EPS (diluted)
- $-3.53
Balance sheet
- Total assets
- $424.4M
- Current assets
- $421.7M
- Total liabilities
- $120.0M
- Current liabilities
- $45.5M
- Shareholders’ equity
- $304.5M
Cash flow
- Operating cash flow
- -$196.0M
- Investing cash flow
- $203.0M
- Financing cash flow
- $146.0M
- Net cash flow
- $153.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-3.53
- Shares outstanding
- 69.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 6, 2022
MoonLake Immunotherapeutics (MLTX) Stock Price
- Reported a net loss of $227.3M.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MoonLake Immunotherapeutics.
Write a review
News about MoonLake Immunotherapeutics
News & sentiment via Polygon.io
MoonLake Immunotherapeutics: frequently asked questions
Is MoonLake Immunotherapeutics an American company?
MoonLake Immunotherapeutics is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is MoonLake Immunotherapeutics publicly traded?
Yes — MoonLake Immunotherapeutics is a publicly traded company. Its stock trades under the ticker symbol MLTX on the NASDAQ.
What does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics is an American Pharmaceuticals company in the Health & Beauty sector.
